Click here to get full coverage on Celcuity (CELC) surges 662% in 2025 on breast cancer treatment trial results - MSN

Celcuity (CELC) surges 662% in 2025 on breast cancer treatment trial results  MSN

Celcuity (CELC) surges 662% in 2025 on breast cancer treatment trial results - MSN

Click here to get full coverage on Income Statement - Intellectia AI

Income Statement - Intellectia AI

Click here to get full coverage on Celcuity (CELC) director Richard Nigon makes bona fide gift of 10,000 shares - Stock Titan

Celcuity (CELC) director Richard Nigon makes bona fide gift of 10,000 shares  Stock Titan

Celcuity (CELC) director Richard Nigon makes bona fide gift of 10,000 shares - Stock Titan

Click here to get full coverage on Is Celcuity (CELC) Still Attractive After Its Strong One Year Share Price Rally - Yahoo Finance

Is Celcuity (CELC) Still Attractive After Its Strong One Year Share Price Rally  Yahoo Finance

Is Celcuity (CELC) Still Attractive After Its Strong One Year Share Price Rally - Yahoo Finance

Click here to get full coverage on Is It Too Late To Consider Celcuity (CELC) After Its Strong Multi‑Year Share Price Run? - simplywall.st

Is It Too Late To Consider Celcuity (CELC) After Its Strong Multi‑Year Share Price Run?  simplywall.st

Is It Too Late To Consider Celcuity (CELC) After Its Strong Multi‑Year Share Price Run? - simplywall.st

Click here to get full coverage on Tudor Investment Corp ET AL Takes $1.35 Million Position in Celcuity, Inc. $CELC - MarketBeat

Tudor Investment Corp ET AL Takes $1.35 Million Position in Celcuity, Inc. $CELC  MarketBeat

Tudor Investment Corp ET AL Takes $1.35 Million Position in Celcuity, Inc. $CELC - MarketBeat

Click here to get full coverage on AI Investing Insights - Official Homepage - Intellectia AI™ - Intellectia AI

AI Investing Insights - Official Homepage - Intellectia AI™  Intellectia AI

AI Investing Insights - Official Homepage - Intellectia AI™ - Intellectia AI

Click here to get full coverage on Why Celcuity (CELC) Is Up 5.5% After Reporting Wider 2025 Losses From Ongoing R&D Spending - simplywall.st

Why Celcuity (CELC) Is Up 5.5% After Reporting Wider 2025 Losses From Ongoing R&D Spending  simplywall.st

Why Celcuity (CELC) Is Up 5.5% After Reporting Wider 2025 Losses From Ongoing R&D Spending - simplywall.st

Click here to get full coverage on Has Celcuity (CELC) Outpaced Other Medical Stocks This Year? - Yahoo Finance

Has Celcuity (CELC) Outpaced Other Medical Stocks This Year?  Yahoo Finance

Has Celcuity (CELC) Outpaced Other Medical Stocks This Year? - Yahoo Finance

Click here to get full coverage on Wells Fargo Initiates Coverage On Celcuity Inc. (CELC) - Yahoo Finance

Wells Fargo Initiates Coverage On Celcuity Inc. (CELC)  Yahoo Finance

Wells Fargo Initiates Coverage On Celcuity Inc. (CELC) - Yahoo Finance

Click here to get full coverage on Assessing Celcuity (CELC) Valuation After FDA Priority Review And Commercial Launch Preparations - simplywall.st

Assessing Celcuity (CELC) Valuation After FDA Priority Review And Commercial Launch Preparations  simplywall.st

Assessing Celcuity (CELC) Valuation After FDA Priority Review And Commercial Launch Preparations - simplywall.st

Click here to get full coverage on Reassessing Celcuity (CELC) Valuation After A 51.85% Three Month Share Price Gain - Yahoo Finance

Reassessing Celcuity (CELC) Valuation After A 51.85% Three Month Share Price Gain  Yahoo Finance

Reassessing Celcuity (CELC) Valuation After A 51.85% Three Month Share Price Gain - Yahoo Finance

Click here to get full coverage on CELC Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI

CELC Financials: Revenue Breakdown, Margins & Competitor Comparison  Intellectia AI

CELC Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI

Click here to get full coverage on Celcuity (CELC) Draws Investor Attention as Precision Oncology Strategy Advances - Yahoo Finance

Celcuity (CELC) Draws Investor Attention as Precision Oncology Strategy Advances  Yahoo Finance

Celcuity (CELC) Draws Investor Attention as Precision Oncology Strategy Advances - Yahoo Finance

Click here to get full coverage on What Celcuity (CELC)'s Gedatolisib Phase 3 Progression-Free Survival Data Means For Shareholders - Yahoo Finance

What Celcuity (CELC)'s Gedatolisib Phase 3 Progression-Free Survival Data Means For Shareholders  Yahoo Finance

What Celcuity (CELC)'s Gedatolisib Phase 3 Progression-Free Survival Data Means For Shareholders - Yahoo Finance

Click here to get full coverage on Celcuity (CELC)’s Clinical Success and M&A Potential Underpin Wolfe Research’s Bullish View - Yahoo Finance

Celcuity (CELC)’s Clinical Success and M&A Potential Underpin Wolfe Research’s Bullish View  Yahoo Finance

Celcuity (CELC)’s Clinical Success and M&A Potential Underpin Wolfe Research’s Bullish View - Yahoo Finance

Click here to get full coverage on (CELC) Movement as an Input in Quant Signal Sets - Stock Traders Daily

(CELC) Movement as an Input in Quant Signal Sets  Stock Traders Daily

(CELC) Movement as an Input in Quant Signal Sets - Stock Traders Daily

Click here to get full coverage on CELCUITY ($CELC) Releases Q4 2025 Earnings | CELC Stock News - Quiver Quantitative

CELCUITY ($CELC) Releases Q4 2025 Earnings | CELC Stock News  Quiver Quantitative

CELCUITY ($CELC) Releases Q4 2025 Earnings | CELC Stock News - Quiver Quantitative

Click here to get full coverage on Celcuity (CELC): Examining Valuation After a 437% Year-to-Date Share Price Surge - Yahoo Finance

Celcuity (CELC): Examining Valuation After a 437% Year-to-Date Share Price Surge  Yahoo Finance

Celcuity (CELC): Examining Valuation After a 437% Year-to-Date Share Price Surge - Yahoo Finance

Click here to get full coverage on Celcuity (CELC) Is Up 7.6% After FDA Accepts Gedatolisib Application for Expedited Review - What's Changed - Yahoo Finance

Celcuity (CELC) Is Up 7.6% After FDA Accepts Gedatolisib Application for Expedited Review - What's Changed  Yahoo Finance

Celcuity (CELC) Is Up 7.6% After FDA Accepts Gedatolisib Application for Expedited Review - What's Changed - Yahoo Finance

Click here to get full coverage on $CELC stock is up 46% today. Here's what we see in our data. - Quiver Quantitative

$CELC stock is up 46% today. Here's what we see in our data.  Quiver Quantitative

$CELC stock is up 46% today. Here's what we see in our data. - Quiver Quantitative

Click here to get full coverage on Assessing Celcuity (CELC): What a 71x Price-to-Book Ratio Says About Valuation - Yahoo Finance

Assessing Celcuity (CELC): What a 71x Price-to-Book Ratio Says About Valuation  Yahoo Finance

Assessing Celcuity (CELC): What a 71x Price-to-Book Ratio Says About Valuation - Yahoo Finance

Click here to get full coverage on Celcuity Inc. (CELC)’s FDA NDA for Gedatolisib Accepted Under RTOR, Accelerating Review - Yahoo Finance

Celcuity Inc. (CELC)’s FDA NDA for Gedatolisib Accepted Under RTOR, Accelerating Review  Yahoo Finance

Celcuity Inc. (CELC)’s FDA NDA for Gedatolisib Accepted Under RTOR, Accelerating Review - Yahoo Finance

Click here to get full coverage on Assessing Celcuity (CELC) Valuation As DCF Outlook Diverges Sharply From Narrative Fair Value - Yahoo Finance

Assessing Celcuity (CELC) Valuation As DCF Outlook Diverges Sharply From Narrative Fair Value  Yahoo Finance

Assessing Celcuity (CELC) Valuation As DCF Outlook Diverges Sharply From Narrative Fair Value - Yahoo Finance

Click here to get full coverage on Nisa Investment Advisors LLC Decreases Stock Holdings in Celcuity, Inc. $CELC - MarketBeat

Nisa Investment Advisors LLC Decreases Stock Holdings in Celcuity, Inc. $CELC  MarketBeat

Nisa Investment Advisors LLC Decreases Stock Holdings in Celcuity, Inc. $CELC - MarketBeat

Click here to get full coverage on Celcuity (CELC) Is Up 52.8% After Promising Phase 3 Breast Cancer Trial Data and FDA Submission Progress. Has The Bull Case Changed? - Yahoo Finance

Celcuity (CELC) Is Up 52.8% After Promising Phase 3 Breast Cancer Trial Data and FDA Submission Progress. Has The Bull Case Changed?  Yahoo Finance

Celcuity (CELC) Is Up 52.8% After Promising Phase 3 Breast Cancer Trial Data and FDA Submission Progress. Has The Bull Case Changed? - Yahoo Finance

Click here to get full coverage on Tudor Investment Corp ET AL Invests $1.35 Million in Celcuity, Inc. $CELC - MarketBeat

Tudor Investment Corp ET AL Invests $1.35 Million in Celcuity, Inc. $CELC  MarketBeat

Tudor Investment Corp ET AL Invests $1.35 Million in Celcuity, Inc. $CELC - MarketBeat

Click here to get full coverage on Celcuity’s Priority Review Puts Gedatolisib And Investor Trade Offs In Focus - simplywall.st

Celcuity’s Priority Review Puts Gedatolisib And Investor Trade Offs In Focus  simplywall.st

Celcuity’s Priority Review Puts Gedatolisib And Investor Trade Offs In Focus - simplywall.st

Click here to get full coverage on Celcuity Inc: A Die To Be Cast Before July 2026 (NASDAQ: CELC) - Seeking Alpha

Celcuity Inc: A Die To Be Cast Before July 2026 (NASDAQ: CELC)  Seeking Alpha

Celcuity Inc: A Die To Be Cast Before July 2026 (NASDAQ: CELC) - Seeking Alpha

Click here to get full coverage on Liquidity Mapping Around (CELC) Price Events - Stock Traders Daily

Liquidity Mapping Around (CELC) Price Events  Stock Traders Daily

Liquidity Mapping Around (CELC) Price Events - Stock Traders Daily

Click here to get full coverage on Celcuity (CELC): Fresh Phase 3 Breast Cancer Data Prompts Closer Look at Gedatolisib-Driven Valuation - Yahoo Finance

Celcuity (CELC): Fresh Phase 3 Breast Cancer Data Prompts Closer Look at Gedatolisib-Driven Valuation  Yahoo Finance

Celcuity (CELC): Fresh Phase 3 Breast Cancer Data Prompts Closer Look at Gedatolisib-Driven Valuation - Yahoo Finance

Click here to get full coverage on Richard Buller Sells 3,000 Shares of Celcuity (NASDAQ:CELC) Stock - MarketBeat

Richard Buller Sells 3,000 Shares of Celcuity (NASDAQ:CELC) Stock  MarketBeat

Richard Buller Sells 3,000 Shares of Celcuity (NASDAQ:CELC) Stock - MarketBeat

Click here to get full coverage on Celcuity's (CELC) "Buy" Rating Reiterated at Needham & Company LLC - MarketBeat

Celcuity's (CELC) "Buy" Rating Reiterated at Needham & Company LLC  MarketBeat

Celcuity's (CELC) "Buy" Rating Reiterated at Needham & Company LLC - MarketBeat

Click here to get full coverage on Stifel Raises Price Target for Celcuity (CELC) to $125, Maintains Buy Rating | CELC Stock News - GuruFocus

Stifel Raises Price Target for Celcuity (CELC) to $125, Maintains Buy Rating | CELC Stock News  GuruFocus

Stifel Raises Price Target for Celcuity (CELC) to $125, Maintains Buy Rating | CELC Stock News - GuruFocus

Click here to get full coverage on Celcuity Stock Pre-Market (-0.2%): Needham Raises Target on Strong Data Publication - Trefis

Celcuity Stock Pre-Market (-0.2%): Needham Raises Target on Strong Data Publication  Trefis

Celcuity Stock Pre-Market (-0.2%): Needham Raises Target on Strong Data Publication - Trefis

Click here to get full coverage on Celcuity Inc. (NASDAQ:CELC) Q4 2025 earnings call transcript - MSN

Celcuity Inc. (NASDAQ:CELC) Q4 2025 earnings call transcript  MSN

Celcuity Inc. (NASDAQ:CELC) Q4 2025 earnings call transcript - MSN

Click here to get full coverage on Celcuity wins FDA review for breast cancer drug (CELC:NASDAQ) - Seeking Alpha

Celcuity wins FDA review for breast cancer drug (CELC:NASDAQ)  Seeking Alpha

Celcuity wins FDA review for breast cancer drug (CELC:NASDAQ) - Seeking Alpha

Click here to get full coverage on Celcuity (Nasdaq: CELC) completes FDA NDA for gedatolisib, cutting progression risk by 76% - Stock Titan

Celcuity (Nasdaq: CELC) completes FDA NDA for gedatolisib, cutting progression risk by 76%  Stock Titan

Celcuity (Nasdaq: CELC) completes FDA NDA for gedatolisib, cutting progression risk by 76% - Stock Titan

Click here to get full coverage on Celcuity (CELC) Projected to Post Earnings on Monday - MarketBeat

Celcuity (CELC) Projected to Post Earnings on Monday  MarketBeat

Celcuity (CELC) Projected to Post Earnings on Monday - MarketBeat

Click here to get full coverage on Why (CELC) Price Action Is Critical for Tactical Trading - Stock Traders Daily

Why (CELC) Price Action Is Critical for Tactical Trading  Stock Traders Daily

Why (CELC) Price Action Is Critical for Tactical Trading - Stock Traders Daily

Click here to get full coverage on Celcuity (NASDAQ:CELC) Price Target Raised to $125.00 - MarketBeat

Celcuity (NASDAQ:CELC) Price Target Raised to $125.00  MarketBeat

Celcuity (NASDAQ:CELC) Price Target Raised to $125.00 - MarketBeat

Click here to get full coverage on Celcuity: What’s Happening With CELC Stock? - Forbes

Celcuity: What’s Happening With CELC Stock?  Forbes

Celcuity: What’s Happening With CELC Stock? - Forbes

Click here to get full coverage on Celcuity (NASDAQ:CELC) Releases Quarterly Earnings Results, Beats Estimates By $0.09 EPS - MarketBeat

Celcuity (NASDAQ:CELC) Releases Quarterly Earnings Results, Beats Estimates By $0.09 EPS  MarketBeat

Celcuity (NASDAQ:CELC) Releases Quarterly Earnings Results, Beats Estimates By $0.09 EPS - MarketBeat

Click here to get full coverage on 3 Stocks You’ll Wish You Bought Before 2026 - MarketBeat

3 Stocks You’ll Wish You Bought Before 2026  MarketBeat

3 Stocks You’ll Wish You Bought Before 2026 - MarketBeat

Click here to get full coverage on (CELC) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily

(CELC) Movement Within Algorithmic Entry Frameworks  Stock Traders Daily

(CELC) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily

Click here to get full coverage on Hennion & Walsh Asset Management Inc. Acquires 19,579 Shares of Celcuity, Inc. $CELC - MarketBeat

Hennion & Walsh Asset Management Inc. Acquires 19,579 Shares of Celcuity, Inc. $CELC  MarketBeat

Hennion & Walsh Asset Management Inc. Acquires 19,579 Shares of Celcuity, Inc. $CELC - MarketBeat

Click here to get full coverage on Celcuity: After Stellar 2025, I Predict More Success In 2026 And Beyond (NASDAQ:CELC) - Seeking Alpha

Celcuity: After Stellar 2025, I Predict More Success In 2026 And Beyond (NASDAQ:CELC)  Seeking Alpha

Celcuity: After Stellar 2025, I Predict More Success In 2026 And Beyond (NASDAQ:CELC) - Seeking Alpha

Click here to get full coverage on Craig-Hallum Maintains Celcuity(CELC.US) With Buy Rating - 富途牛牛

Craig-Hallum Maintains Celcuity(CELC.US) With Buy Rating  富途牛牛

Craig-Hallum Maintains Celcuity(CELC.US) With Buy Rating - 富途牛牛

Click here to get full coverage on Avoiding Lag: Real-Time Signals in (CELC) Movement - Stock Traders Daily

Avoiding Lag: Real-Time Signals in (CELC) Movement  Stock Traders Daily

Avoiding Lag: Real-Time Signals in (CELC) Movement - Stock Traders Daily

Click here to get full coverage on Celcuity Inc. (NASDAQ:CELC) Q4 2025 Earnings Call Transcript - Insider Monkey

Celcuity Inc. (NASDAQ:CELC) Q4 2025 Earnings Call Transcript  Insider Monkey

Celcuity Inc. (NASDAQ:CELC) Q4 2025 Earnings Call Transcript - Insider Monkey

Click here to get full coverage on 7.3‑month PFS gain — Celcuity's gedatolisib triplet cuts progression/death risk 76% in Phase 3 - Stock Titan

7.3‑month PFS gain — Celcuity's gedatolisib triplet cuts progression/death risk 76% in Phase 3  Stock Titan

7.3‑month PFS gain — Celcuity's gedatolisib triplet cuts progression/death risk 76% in Phase 3 - Stock Titan

Click here to get full coverage on Celcuity Stock Up 677% in 6 Months: What's Behind This Huge Increase? - Yahoo Finance

Celcuity Stock Up 677% in 6 Months: What's Behind This Huge Increase?  Yahoo Finance

Celcuity Stock Up 677% in 6 Months: What's Behind This Huge Increase? - Yahoo Finance

Click here to get full coverage on Needham raises Celcuity stock price target on priority review status - Investing.com

Needham raises Celcuity stock price target on priority review status  Investing.com

Needham raises Celcuity stock price target on priority review status - Investing.com

Click here to get full coverage on Celcuity soars on phase 3 data for gedatolisib in breast cancer (CELC:NASDAQ) - Seeking Alpha

Celcuity soars on phase 3 data for gedatolisib in breast cancer (CELC:NASDAQ)  Seeking Alpha

Celcuity soars on phase 3 data for gedatolisib in breast cancer (CELC:NASDAQ) - Seeking Alpha

Click here to get full coverage on A Look at Celcuity (CELC) Valuation After FDA Review Triggered by VIKTORIA-1 Breast Cancer Trial Results - simplywall.st

A Look at Celcuity (CELC) Valuation After FDA Review Triggered by VIKTORIA-1 Breast Cancer Trial Results  simplywall.st

A Look at Celcuity (CELC) Valuation After FDA Review Triggered by VIKTORIA-1 Breast Cancer Trial Results - simplywall.st

Click here to get full coverage on European Regional CELC Conference - WELS

European Regional CELC Conference  WELS

European Regional CELC Conference - WELS

Click here to get full coverage on CELCUITY INC (NASDAQ:CELC) Stock Surges 70% in a Month Following Q3 Earnings Beat and Positive Clinical Data - ChartMill

CELCUITY INC (NASDAQ:CELC) Stock Surges 70% in a Month Following Q3 Earnings Beat and Positive Clinical Data  ChartMill

CELCUITY INC (NASDAQ:CELC) Stock Surges 70% in a Month Following Q3 Earnings Beat and Positive Clinical Data - ChartMill

Click here to get full coverage on Celcuity: From Speculative Bet To Pre-Commercial Powerhouse (NASDAQ:CELC) - Seeking Alpha

Celcuity: From Speculative Bet To Pre-Commercial Powerhouse (NASDAQ:CELC)  Seeking Alpha

Celcuity: From Speculative Bet To Pre-Commercial Powerhouse (NASDAQ:CELC) - Seeking Alpha

Click here to get full coverage on CRMD, RANI, CELC, RAPT: four biotech stocks flying high today and why - Invezz

CRMD, RANI, CELC, RAPT: four biotech stocks flying high today and why  Invezz

CRMD, RANI, CELC, RAPT: four biotech stocks flying high today and why - Invezz

Click here to get full coverage on Investment Manager Loads Up on CELC Stock, Adds 135,000 Shares, According to Latest SEC Filing - The Motley Fool

Investment Manager Loads Up on CELC Stock, Adds 135,000 Shares, According to Latest SEC Filing  The Motley Fool

Investment Manager Loads Up on CELC Stock, Adds 135,000 Shares, According to Latest SEC Filing - The Motley Fool

Click here to get full coverage on Celcuity Inc. Reports Release of Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update - GlobeNewswire

Celcuity Inc. Reports Release of Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update  GlobeNewswire

Celcuity Inc. Reports Release of Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update - GlobeNewswire

Click here to get full coverage on Earnings Flash (CELC) Celcuity Inc. Posts Q3 Adjusted Loss $0.78 per Share, vs. FactSet Est of $-0.96 - marketscreener.com

Earnings Flash (CELC) Celcuity Inc. Posts Q3 Adjusted Loss $0.78 per Share, vs. FactSet Est of $-0.96  marketscreener.com

Earnings Flash (CELC) Celcuity Inc. Posts Q3 Adjusted Loss $0.78 per Share, vs. FactSet Est of $-0.96 - marketscreener.com

Click here to get full coverage on Celcuity To Participate in Upcoming Investor Conferences - GlobeNewswire

Celcuity To Participate in Upcoming Investor Conferences  GlobeNewswire

Celcuity To Participate in Upcoming Investor Conferences - GlobeNewswire

Click here to get full coverage on Celcuity Inc. Appoints New Independent Director - TradingView — Track All Markets

Celcuity Inc. Appoints New Independent Director  TradingView — Track All Markets

Celcuity Inc. Appoints New Independent Director - TradingView — Track All Markets

Click here to get full coverage on Why Celcuity Stock Popped Today - The Motley Fool

Why Celcuity Stock Popped Today  The Motley Fool

Why Celcuity Stock Popped Today - The Motley Fool

Click here to get full coverage on Celcuity Stock Near All-Time Highs — And This Major Biotech Investor Is Still Jumping In - The Motley Fool

Celcuity Stock Near All-Time Highs — And This Major Biotech Investor Is Still Jumping In  The Motley Fool

Celcuity Stock Near All-Time Highs — And This Major Biotech Investor Is Still Jumping In - The Motley Fool

Click here to get full coverage on Today's Pre-Market Movers and Top Ratings | VAPE, CELC, SBET, and More - Moomoo

Today's Pre-Market Movers and Top Ratings | VAPE, CELC, SBET, and More  Moomoo

Today's Pre-Market Movers and Top Ratings | VAPE, CELC, SBET, and More - Moomoo

Click here to get full coverage on Top 1% Celcuity Stock Shoots To Record High On Roche-Rivaling Breast Cancer Results - Investor's Business Daily

Top 1% Celcuity Stock Shoots To Record High On Roche-Rivaling Breast Cancer Results  Investor's Business Daily

CELC

Price Chart

Key Statistics

Technicals

About CELC

Latest News

Celcuity (CELC) surges 662% in 2025 on breast cancer treatment trial results - MSN

Income Statement - Intellectia AI

Celcuity (CELC) director Richard Nigon makes bona fide gift of 10,000 shares - Stock Titan

Advanced Charts

Top Gainers

Top Losers